YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
This article first appeared on GuruFocus. Revenue: $32.4 million for the quarter ended June 30, 2026, in line with the previous three quarters. Operating Profit: $7.5 million, consistent with recent quarters. Research and Development (R&D)…
Key Points Interested in Elite Pharmaceuticals Inc.? Here are five stocks we like better. Steady financial performance: Elite Pharmaceuticals reported fiscal Q1 2027 revenue of $32.4 million and operating profit of $7.5 million, broadly co…
Shares of Elite Pharmaceuticals, Inc. ELTP have lost 13.7% since the company reported earnings for the fiscal year ended March 31, 2026, underperforming the S&P 500 Index, which gained 1.8% over the same period. The stock has also trailed…
Earnings Call Insights: Elite Pharmaceuticals (ELTP) Q4 fiscal 2026 MANAGEMENT VIEW * "Total revenues for the year were $149 million" and Elite delivered "operating income was $49 million" while "operating cash flow this year was positive…
* Elite Pharmaceuticals press release [https://seekingalpha.com/pr/20567351-elite-pharmaceuticals-inc-reports-financial-results-for-the-fiscal-year-ended-march-31-2026] (ELTP [https://seekingalpha.com/symbol/ELTP]): FY GAAP EPS of $0.03. *…
The market has climbed 1.2% in the last 7 days and is up 33% over the last 12 months, with earnings forecast to grow by 16% annually. Investing in penny stocks can still open doors to growth opportunities, typically in smaller or newer com…
For Immediate Release Chicago, IL – March 18, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial ma…
Tuesday, March 17, 2026 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including GE Aerospace (GE), Shell plc (SHEL) and McKesson Cor…
As February begins, the U.S. stock market has shown a robust start with major indexes like the Dow Jones and S&P 500 posting significant gains. For investors interested in exploring beyond well-known stocks, penny stocks—often associated w…
As the U.S. stock market wraps up a holiday-shortened week with notable gains across major indexes, investors are taking stock of opportunities that may have flown under the radar. Penny stocks, while an old term, continue to intrigue due…
As U.S. stock indexes hit record highs amid optimism over trade discussions between the U.S. and China, investors are increasingly looking for opportunities beyond the major indices. Penny stocks, often associated with smaller or newer com…
Despite a recent dip, major U.S. stock indexes remain near their all-time highs, reflecting a resilient market even as inflationary pressures persist. In this context, penny stocks—often representing smaller or newer companies—offer unique…
For Immediate Release Chicago, IL – August 28, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial m…
Wednesday, August 27, 2025 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc. (BRK.B), Toyota Motor Cor…
As the U.S. stock market experiences a downturn with the S&P 500 declining for a fourth consecutive day, investors are keenly focused on upcoming signals from Federal Reserve Chair Jerome Powell regarding interest rates. In such fluctuatin…
* Elite Pharmaceuticals press release [https://seekingalpha.com/pr/20202001-elite-pharmaceuticals-inc-reports-financial-results-for-the-first-quarter-of-fiscal-year-2026] (OTCQB:ELTP [https://seekingalpha.com/symbol/ELTP]): Q1 GAAP EPS of…
Here we highlight 2 small cap stocks with Zacks’ Outperform ratings that pulled back despite recent quarterly announcements which were arguably strong but a bit noisy. Elite Pharmaceuticals Inc. (ELTP) is a manufacturer of generic drugs. I…
Elite Pharmaceuticals NASDAQ:ELTP Chief Commercial Officer Kirko Kirkov reported purchasing 16,366 shares of common stock on July 10, 2025. The shares were bought at a price of $0.589, totaling $9639. The purchase comes as the company show…
For Immediate Release Chicago, IL – July 25, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial mar…
Thursday, July 24, 2025 The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Cisco Systems, Inc. (CSCO), Caterpillar Inc. (CAT) a…
Elite Pharmaceuticals reported significant financial growth during its Q1 2025 earnings call, with a 52% increase in total revenues, reaching 84 million dollars. According to InvestingPro data, the company has maintained strong momentum wi…
* Elite Pharmaceuticals press release [https://seekingalpha.com/pr/20152497-elite-pharmaceuticals-inc-reports-financial-results-for-the-fiscal-year-ended-march-31-2025] (OTCQB:ELTP [https://seekingalpha.com/symbol/ELTP]): FY Revenue of $84…
Financials for Fiscal Year 2025 Ended March 31, 2025 will be released on Monday, June 30, 2025 Northvale, Northvale, New Jersey--(Newsfile Corp. - June 23, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a spe…
NORTHVALE, N.J., March 11, 2019 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB: ELTP) announced today that it has entered into a license, supply, and distribution agreement (“Agreement”) with Lannett Comp…
Conference Call Scheduled for Tuesday, February 12th at 11:30 AM EST NORTHVALE, N.J., Feb. 11, 2019 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB: ELTP), a specialty pharmaceutical company developing abu…
Northvale, NJ, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCQB: ELTP), a specialty pharmaceutical company developing a pipeline of abuse-deterrent opioids and niche generic products, announce…
NORTHVALE, N.J., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB: ELTP) a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today announced that…
NORTHVALE, N.J., Dec. 10, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB: ELTP) a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today announced that…
NORTHVALE, N.J., Nov. 20, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB: ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today announced that…
Conference Call Scheduled for Monday, November 12th at 11:30 AM EST NORTHVALE, N.J., Nov. 09, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB: ELTP), a specialty pharmaceutical company developing abus…
Financials for Second Quarter Fiscal Year 2019 Ended September 30, 2018 will be released November 9, 2018 NORTHVALE, N.J, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCQB: ELTP), a specialty p…
NORTHVALE, N.J., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB: ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today announced the…
NORTHVALE, N.J., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB: ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today reported posit…
NORTHVALE, N.J., Sept. 18, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB: ELTP) a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today announced that…
NORTHVALE, N.J., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB: ELTP) a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today reported positi…
NORTHVALE, N.J., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB: ELTP), a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, announced results fo…